Health
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer – EurekAlert
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung…
IMAGE: Tina Cascone, M.D., Ph.D.
view more
Credit: MD Anderson Cancer Center
HOUSTON — The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas…
-
Noosa News7 hours agoHow Lily Steele-Park took her rapist to court and won
-
General21 hours ago‘Potential’ hacker contacts Qantas over data breach
-
Business11 hours agoFord CEO makes stunning prediction about artificial intelligence
-
Business22 hours ago5 amazing ASX ETFs for Aussie investors in July